Cargando…

Human papillomavirus prevalence in oral and oropharyngeal squamous cell carcinoma in South America: A systematic review and meta-analysis

Some studies have addressed the prevalence of human papillomavirus (HPV) in head and neck cancer in South America; however, no studies have systematically gathered prevalence and conducted a meta-analysis. This study aims to estimate the prevalence of HPV in oral and oropharyngeal squamous cell carc...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Antônio Carlos, Cavalcanti de Lima, Israel Carlos, Frez Marques, Vitor Marcelo, Alves de Araújo, Wudson Henrique, de Campos Ferreira, Chrystiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012143/
https://www.ncbi.nlm.nih.gov/pubmed/35432780
http://dx.doi.org/10.4081/oncol.2022.552
Descripción
Sumario:Some studies have addressed the prevalence of human papillomavirus (HPV) in head and neck cancer in South America; however, no studies have systematically gathered prevalence and conducted a meta-analysis. This study aims to estimate the prevalence of HPV in oral and oropharyngeal squamous cell carcinomas in South America. We performed a systematic review and metaanalysis using the following databases: PubMed, Embase, Lilacs, Medline, Scopus, and Web of Science. Data were extracted and analyzed using random-effects models to estimate the pooled prevalence of HPV. We identified 209 nonduplicated studies, of which 38 were selected. The overall prevalence of HPV was 24.31% (95% CI 16.87–32.64; I(2) = 96%, p(heterogeneity) <0.001). HPV prevalence in oropharyngeal cancer was 17.9% (95% CI 7.6–31.4; I(2) = 96%, p(heterogeneity) <0.001) and that in oral cavity cancer was 23.19% (95% CI 14.94–32.63; I(2) = 94%, p(heterogeneity) <0.001). We found an overall prevalence of HPV in 24.31% of oral and oropharyngeal squamous cell carcinomas in South American patients. The prevalence of HPV was 17.9% for oropharyngeal cancer and 23.19% for oral cavity cancer.